Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 20
Eur J Dermatol ; 31(6): 736-740, 2021 Dec 01.
Article in English | MEDLINE | ID: covidwho-1496704


Dupilumab is an effective treatment for atopic dermatitis and was found to improve results of clinician- and patient-oriented tests with relevant benefits across multiple domains related to the disease. To investigate the effects of significant psychological stress on clinician- and patient-oriented tests for severe AD patients treated with dupilumab. Patients were investigated before and during the COVID-19 pandemic and lockdown in a severely affected area. Forty-five adult patients suffering from severe AD were enrolled. Clinician-oriented (EASI, SCORAD and NRS scores for sleep loss and itching) and patient-oriented tests (DLQI, POEM and HADS) were administered at baseline (T0) and after 16 (T1) and 24 (T2) weeks. The T2 examination took place just before the outbreak of the COVID-19 pandemic. A further examination took place at 32 weeks (T3) during the COVID-19 pandemic and lockdown. In comparison to baseline, dupilumab treatment rapidly improved the scores of all tests. After this, the pandemic and lockdown started, and scores of clinician-oriented tests remained almost stable, while patient-oriented scores markedly deteriorated, although they remained better than at baseline. Some personal and social situations seemed to be linked to a worse result. Despite dupilumab being effective in inducing and maintaining clinical remission of AD, the COVID-19 pandemic and lockdown significantly impaired patients' perception of the disease, quality of life and anxiety and/or depression. However, this psychological status did not modify the therapeutic response to dupilumab.

Antibodies, Monoclonal, Humanized/therapeutic use , Dermatitis, Atopic/drug therapy , Pandemics , Quality of Life , Quarantine/psychology , COVID-19 , Dermatologic Agents/therapeutic use , Humans , Remission Induction
Adv Skin Wound Care ; 34(10): 517-524, 2021 Oct 01.
Article in English | MEDLINE | ID: covidwho-1429312


GENERAL PURPOSE: To present a scoping review of preclinical and clinical trial evidence supporting the efficacy and/or safety of major alternative wound care agents to summarize their effects on validated elements of wound bed preparation and wound management paradigms. TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant will:1. Differentiate the effectiveness of the topical wound care agents included in this review.2. Compare the preventive efficacy of intravenous agents administered to trauma and surgical patients.3. Select the effectiveness of products in this review that are left in place after surgical procedures.4. Identify an oral agent that can be helpful in mitigating the effects of COVID-19.

Effective wound healing is achieved by well-timed host, cell, and environment interactions involving hemostasis, inflammation, formation of repaired dermal structures, and epithelialization, followed by months to years of scar remodeling. Globally, various natural or synthetic agents or dressings are used to optimize wound environments, prolong drug release, aid in fluid absorption, provide favorable healing environments, and act as a mechanical barrier against wound trauma. In this scoping review of evidence from the PubMed and databases, authors examined clinical study evidence supporting the efficacy and safety of selected phytochemicals, vehicles, polymers, and animal products considered "naturally derived" or "alternative" wound interventions to provide a summary of preclinical evidence. Agents with the most clinical evidence were honey, alginates, polyurethane, gelatin, and dextran. Practice implications are described in the context of the TIMERS clinical paradigm.

Dermatologic Agents/therapeutic use , Skin Care/methods , Wound Healing/physiology , Wounds and Injuries/therapy , Anti-Infective Agents/therapeutic use , COVID-19/epidemiology , Disease Management , Humans
J Drugs Dermatol ; 19(9): 889-892, 2020 Sep 01.
Article in English | MEDLINE | ID: covidwho-1231668


Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially drugs approved for previous emergence of the severe acute respiratory syndrome (SARS-CoV-1) and Middle east respiratory syndrome coronavirus (MERS-Cov). Numerous active clinical trials for COVID-19 with more than 150 drugs and products are under study. Needless to say, many dermatological drugs are being employed to mitigate this pandemic threat. We aim to review drugs with potential against SARS-Cov-2 widely used in dermatology practice. Additionally, rampant and overzealous use of these drugs as well as introduction of new molecules might lead to emergence of adverse effects associated with these agents. Dermatologists must be on lookout for any cutaneous adverse effects of these drugs. J Drugs Dermatol. 2020;19(9):889-892. doi:10.36849/JDD.2020.5323.

Antiviral Agents/adverse effects , Coronavirus Infections/drug therapy , Coronavirus Infections/epidemiology , Dermatologic Agents/adverse effects , Drug Eruptions/etiology , Pneumonia, Viral/drug therapy , Pneumonia, Viral/epidemiology , Severe Acute Respiratory Syndrome/drug therapy , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/adverse effects , Adenosine Monophosphate/analogs & derivatives , Alanine/administration & dosage , Alanine/adverse effects , Alanine/analogs & derivatives , Antiviral Agents/therapeutic use , Biological Products/administration & dosage , Biological Products/adverse effects , COVID-19 , Dermatologic Agents/therapeutic use , Drug Eruptions/epidemiology , Drug Eruptions/physiopathology , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Incidence , Male , Pandemics , Prognosis , Risk Assessment , Severe Acute Respiratory Syndrome/diagnosis , Severe Acute Respiratory Syndrome/epidemiology
Dermatol Ther ; 33(6): e14472, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-894746


During COVID-19 outbreak hospitals were congested and infliximab was interrupted. Thus, we performed this observational study to understand the consequent burden of complications in these special cluster of psoriatic patients. We followed up 56 psoriatic patients who were receiving Infliximab treatment by telephone. The majority of patients had lesions exacerbation, accompanied by anxiety emotion. It is suggested that reserving common drugs for psoriasis at home is necessary. Besides, telemedicine should be advocated as a main medical visit mode during the outbreak of COVID-19.

COVID-19 , Dermatologic Agents/therapeutic use , Health Services Accessibility , Infliximab/therapeutic use , Psoriasis/drug therapy , Telemedicine , Adult , Dermatologic Agents/supply & distribution , Drug Substitution , Female , Humans , Male , Middle Aged , Psoriasis/diagnosis , Psoriasis/immunology , Treatment Outcome
Clin Dermatol ; 38(6): 731-733, 2020.
Article in English | MEDLINE | ID: covidwho-785353


In late 2019, the coronavirus disease 2019 (COVID-19) broke out in Wuhan and then spread over China, which greatly affected the medical practices and health care systems. With most of the hospital's outpatient services closed, the routine clinical diagnosis and treatment for patients with dermatomyositis has been disturbed. We conducted telephone follow-up for 52 patients to know the changes in the condition and the continuation of drug therapy and to ensure the continuity, safety, and effectiveness of the treatment of patients with dermatomyositis during COVID-19.

COVID-19/epidemiology , Dermatologic Agents/therapeutic use , Dermatomyositis/drug therapy , Adult , Aged , China/epidemiology , Dermatologic Agents/adverse effects , Disease Outbreaks , Female , Humans , Male , Medication Adherence , Middle Aged , SARS-CoV-2 , Telemedicine
Dermatol Ther ; 33(6): e13972, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-631351


Severe acute respiratory syndrome coronavirus 2 is the coronavirus strain that causes coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) has designated the ongoing COVID-19 outbreak a Public Health Emergency of International Concern. WHO declared COVID-19 as a pandemic on 11 March 2020. During the pandemic and lockdown period, many dermatologic clinics were temporarily closed in Turkey as well as all over the world. Taking the necessary precautions, the hospital continued to examine all emergent and elective patients who applied to our dermatology clinic. We investigated the most common reasons for admission of pediatric and adult patients who were admitted to our outpatient clinic between 30 March and 30 April 2020, the period with the highest number of COVID-19 patients in Turkey. In children and adult age groups, the most common reason for admission was acne (N: 10 [16.4%] and N: 89 [20.9%], respectively). Of the 99 acne patients, 70 (70.7%) were using systemic isotretinoin and applied to our clinic to repeat the prescription or continue the agent. The number of pediatric patients admitted to the dermatology department drastically reduced during the lockdown period, which was attributed to the curfew for children in the country.

COVID-19/epidemiology , Dermatology/trends , Hospitals, University/trends , Outpatient Clinics, Hospital/trends , Skin Diseases/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Appointments and Schedules , COVID-19/diagnosis , Child , Child, Preschool , Dermatologic Agents/therapeutic use , Drug Prescriptions , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Retrospective Studies , Skin Diseases/diagnosis , Skin Diseases/drug therapy , Time Factors , Turkey/epidemiology , Young Adult